Literature DB >> 10618425

Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis.

N Seo1, Y Tokura, T Nishijima, H Hashizume, F Furukawa, M Takigawa.   

Abstract

H-2K(b)-restricted tumor epitope peptides, including tyrosinase-related protein 2 residues 181-188 (TRP-2) and connexin 37 residues 52-59 (MUT1), were applied to permeability barrier-disrupted C57BL/6 (B6) mouse skin from which the stratum corneum of the epidermis had been removed by tape-stripping. This procedure primed tumor-specific cytotoxic T lymphocytes (CTLs) in the lymph nodes and spleen, protected mice against subsequent challenge with corresponding tumor cells, and suppressed the growth of established tumors. Preventive and therapeutic effectiveness was correlated with the frequency of tumor-specific CTL precursors. MHC class II Ia(b+) cells separated from tape-stripped skin, compared with those from intact skin, exhibited a strong antigen-presenting capacity for CTL, suggesting that CTL expansion after peptide application is primarily mediated by epidermal Langerhans cells. Thus, percutaneous peptide immunization via barrier-disrupted skin provides a simple and noninvasive means of inducing potent anti-tumor immunity which may be exploited for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618425      PMCID: PMC26670          DOI: 10.1073/pnas.97.1.371

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.

Authors:  K L Rock; K Clark
Journal:  J Immunol       Date:  1996-05-15       Impact factor: 5.422

2.  Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity.

Authors:  C M Celluzzi; L D Falo
Journal:  J Invest Dermatol       Date:  1997-05       Impact factor: 8.551

3.  Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.

Authors:  S K Nair; D Boczkowski; D Snyder; E Gilboa
Journal:  Eur J Immunol       Date:  1997-03       Impact factor: 5.532

4.  Enhancement of delayed-type hypersensitivity to sheep red blood cells in mice by granulocyte colony-stimulating factor administration at the elicitation phase.

Authors:  M Terashita; C Kudo; T Yamashita; I Gresser; F Sendo
Journal:  J Immunol       Date:  1996-06-15       Impact factor: 5.422

5.  Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity.

Authors:  J W Young; K Inaba
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

6.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.

Authors:  D Boczkowski; S K Nair; D Snyder; E Gilboa
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

7.  Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.

Authors:  M B Bloom; D Perry-Lalley; P F Robbins; Y Li; M el-Gamil; S A Rosenberg; J C Yang
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

8.  Differential antigen recognition by T cells from the spleen and central nervous system of coronavirus-infected mice.

Authors:  R F Castro; S Perlman
Journal:  Virology       Date:  1996-08-01       Impact factor: 3.616

9.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Authors:  L Zitvogel; J I Mayordomo; T Tjandrawan; A B DeLeo; M R Clarke; M T Lotze; W J Storkus
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

10.  Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.

Authors:  P Paglia; C Chiodoni; M Rodolfo; M P Colombo
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more
  16 in total

1.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.

Authors:  Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller; Charalambos D Partidos
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

2.  Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Authors:  Igor M Belyakov; Scott A Hammond; Jeffrey D Ahlers; Gregory M Glenn; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

3.  The Langerhans cell controversy: are they immunostimulatory or immunoregulatory cells of the skin immune system?

Authors:  Patrizia Stoitzner
Journal:  Immunol Cell Biol       Date:  2010 May-Jun       Impact factor: 5.126

Review 4.  Langerhans cells as targets for immunotherapy against skin cancer.

Authors:  Patrizia Stoitzner; Florian Sparber; Christoph H Tripp
Journal:  Immunol Cell Biol       Date:  2010-03-30       Impact factor: 5.126

5.  Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines.

Authors:  Z Shi; M Zeng; G Yang; F Siegel; L J Cain; K R van Kampen; C A Elmets; D C Tang
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Langerhans cells cross-present antigen derived from skin.

Authors:  Patrizia Stoitzner; Christoph H Tripp; Andreas Eberhart; Kylie M Price; Jae Y Jung; Laura Bursch; Franca Ronchese; Nikolaus Romani
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-03       Impact factor: 11.205

7.  Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.

Authors:  Galit Eisenberg; Arthur Machlenkin; Shoshana Frankenburg; Adva Mansura; Jacob Pitcovski; Eitan Yefenof; Tamar Peretz; Michal Lotem
Journal:  Cell Immunol       Date:  2010-09-18       Impact factor: 4.868

8.  Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge.

Authors:  A S Beignon; J P Briand; S Muller; C D Partidos
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

9.  Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197), of diphtheria toxin.

Authors:  S Godefroy; M Peyre; N Garcia; S Muller; D Sesardic; C D Partidos
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

10.  Layer-by-layer-assembled multilayer films for transcutaneous drug and vaccine delivery.

Authors:  Xingfang Su; Byeong-Su Kim; Sara R Kim; Paula T Hammond; Darrell J Irvine
Journal:  ACS Nano       Date:  2009-11-24       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.